How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about avapritinib

Marketing authorisation indication

2.1

Avapritinib (Ayvakyt, Blueprint Medicines) is indicated for 'the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment'.

Price

2.3

£26,667.00 for a 30-pack of 25 mg tablets (excluding VAT; BNF online accessed May 2026).

2.4

The company has a commercial arrangement. This makes avapritinib available to the NHS with a discount and it would have also applied to this indication if avapritinib had been recommended. The size of the discount is commercial in confidence.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Blueprint Medicines will be included here when guidance is published.